期刊文献+

洛伐他汀对慢性肾脏病患者尿白细胞介素-6的影响

THE EFFECTS OF LOVASTATIN ON INTERLEUKIN-6 IN PATIENTS OF CHRONIC KIDNEY DISEASE
下载PDF
导出
摘要 目的观察洛伐他汀对慢性肾脏病(CKD)患者尿白细胞介素-6(IL-6)的影响,探讨他汀类药物对肾脏的保护作用.方法将血脂正常的CKD患者89例随机分成两组,治疗组在综合治疗的基础上口服洛伐他汀(20~40mg/d),对照组维持综合治疗,疗程为6个月.观察治疗前后尿IL-6的变化.结果治疗组尿IL-6显著下降(P<0.05),肾功能改善,血脂无明显变化;对照组各指标无明显变化.结论洛伐他汀有非降脂的肾保护作用,改善肾功能. Objective To explore the curative effects of lovastatin on urinary interleukin-6 (IL-6) in patients of chronic kidney disease (CKD). 89cases of CKD with normal blood-lipid levels were randomly divided into two groups. The treatment group were treated with lavostation(20-40mg/d) in addition to the comprehensive treatment. The contrast group received comprehensive treatment only. The courses of treatment were 6 months in both groups. The changes of IL-6 before and after treatments were observed. MethodsResults The level of IL-6 in the treatment group delined significantly (P〈0.05). The renal functions were improved greatly and no obvious changes in blood-lipid level were found, while the indexes in the contrast group remained unchanged. Conclusion Lovastatin can be used to protect and improve the renal functions.
出处 《临沂医学专科学校学报》 2005年第5期337-339,共3页 Journal of Linyi Medical College
关键词 洛伐他汀 慢性肾脏病 白细胞介素-6 Lovastatin Chronic Kidney disease Interleukin-6
  • 相关文献

参考文献10

  • 1Yukawa S, Mune M, Yamada Y, et al. Ongoing clinical trials of lipid reduction therapy in patients with renal disease [ J ]. Kidney Int, 1999,71(Suppl 1) :S141-143.
  • 2Elisaf M, Mikhailids DP. Statins and renal function[J]. Angiology,2002,53(5) :493-502.
  • 3Nakamura T, Ushiyama C, Hirokawa K, et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis[ J ]. Nephrol Dial Transplant, 2002, 17 ( 5 ):798-802.
  • 4宋海翔,王子芬,张凤芳,周慧.慢性肾功能衰竭患者尿白细胞介素-6的检测及大黄对其影响[J].中国中西医结合杂志,2000,20(2):107-109. 被引量:60
  • 5李航,李学旺,段琳,李艳,陈崴.洛伐他汀对系膜细胞核因子-κB活性及炎性细胞因子表达的影响[J].中华肾脏病杂志,2001,17(4):242-245. 被引量:35
  • 6Danesh FR, Sadeghi MM, Amro N, et al. 3-Hyd roxy-3-methylutaryl CoA reductase inhibitors preventhigh glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signalingpathway: Implications for diabetic nephropathy [ J ]. Proc Natl Acad Sci USA, 2002,99 (12) : 8301-5.
  • 7Imura O, Vrtovsnik F, Terzi F. HMG-CoA reductase inhibitor induce apoptosis in mouse proximaltubular cells in primary culture[J]. Kidney Int, 1997,52(5) :962-969.
  • 8Kim SI,Kim HJ ,Han DC, et al. Effect of lovastatin on small GTP binding proteins and on TGF-βand fibronectin expression[ J ]. Kidney Int, 2000,58 (Suppl 71 ): S88-92.
  • 9Usui H, Shikata K, Matsuda M, et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats[ J ]. Nephrol Dial Transplant, 2003,18 ( 1 ): 265-272.
  • 10Oda H, Keane WF, Recent advances in statins and the kidney[J]. Kidney Int, 1999,56(Suppl71) :S2-5.

二级参考文献9

共引文献93

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部